Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study
Sylvain Lamure, Rémy Duléry, Roberta Di Blasi, Adrien Chauchet, Cécile Laureana, Bénédicte Deau-Fischer, Bernard Drenou, Carole Soussain, Cédric Rossi, Nicolas Noël, Sylvain Choquet, Serge Bologna, Bertrand Joly, Milena Kohn, Sandra Malak, Guillemette Fouquet, Etienne Daguindau, Sophie Bernard, Catherine Thiéblemont, Guillaume Cartron, Karine Lacombe, Caroline Besson, Sylvain Lamure, Rémy Duléry, Roberta Di Blasi, Adrien Chauchet, Cécile Laureana, Bénédicte Deau-Fischer, Bernard Drenou, Carole Soussain, Cédric Rossi, Nicolas Noël, Sylvain Choquet, Serge Bologna, Bertrand Joly, Milena Kohn, Sandra Malak, Guillemette Fouquet, Etienne Daguindau, Sophie Bernard, Catherine Thiéblemont, Guillaume Cartron, Karine Lacombe, Caroline Besson
Abstract
Background: Patients with lymphoma are immunocompromised because of the disease per se and its treatments. We aimed to describe the characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and to analyze pre-Covid-19 determinants of mortality.
Methods: This retrospective multicentric cohort study used the Programme de Médicalisation des Systèmes d'Information database to identify all adult patients with lymphoma, hospitalized for Covid-19 in March and April 2020, in 12 hospitals of three French regions with pandemic outbreaks. The characteristics of lymphoma and Covid-19 were collected from medical charts.
Findings: Eighty-nine patients were included. The median age was 67 years (range, 19-92), 66% were male and 72% had a comorbidity. Most patients had B-cell non-Hodgkin lymphoma (86%) and had received a lymphoma treatment within one year (70%). With a median follow-up of 33 days from admission, 30-day overall survival was 71%, (95% confidence interval, 62-81%). In multivariable analysis, having an age ≥ 70 years (hazard ratio 2·87, 1·20-6·85, p = 0·02) and relapsed/refractory lymphoma (hazard ratio 2·54, 1·14-5·66, p = 0·02) were associated with mortality. Recent bendamustine treatment (n = 9) was also pejorative (hazard ratio 3·20, 1·33-7·72, p = 0·01), but was strongly associated with relapsed/refractory lymphoma. Remarkably, 30-day overall survival for patients < 70 years of age without relapsed/refractory lymphoma was 88% (78% - 99%).
Interpretation: Thirty-day mortality was associated with being older and relapsed/refractory lymphoma. Survival of patients younger than 70 years without relapsed/refractory lymphoma was comparable to that of the general population.
Funding: There have been no specific funds to run this study.
Conflict of interest statement
The authors certify that there is no conflict of interest with any organization regarding the material presented in this manuscript. Rémy Duléry reports personal fees from Takeda, non-financial support from Gilead, personal fees from Novartis, outside the submitted work. Roberta Di Blasi reports personal fees from Gilead, personal fees from Novartis, outside the submitted work. Sylvain Choquet reports personal fees from Sanofi, personal fees from Celgene, personal fees from Roche, personal fees from Abbvie, personal fees from Sandoz, personal fees from Janssen, personal fees from Takeda, personal fees from Sandoz, outside the submitted work. Serge Bologna reports personal fees from Janssen, personal fees from Roche, outside the submitted work. Sophie Bernard reports non-financial support from Janssen, outside the submitted work. Guillaume Cartron reports personal fees from Roche, Celgene, Sanofi, Gilead, Janssen, and Abbvie, outside the submitted work. Karine Lacombe reports personal fees and non-financial support from Gilead, personal fees and non-financial support from MSD, personal fees and non-financial support from Abbvie, personal fees and non-financial support from ViiV Healthcare, personal fees and non-financial support from Janssen, outside the submitted work. Caroline Besson reports non-financial support from Takeda, outside the submitted work. All other authors have nothing to disclose.
© 2020 The Author(s).
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7599303/bin/gr1.jpg)
Fig. 2
Overall survival of patients with…
Fig. 2
Overall survival of patients with Covid-19 and lymphoma ( N = 89), according…
- Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.Duléry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, Rossi C, Drenou B, Deau Fischer B, Soussain C, Feugier P, Noël N, Choquet S, Bologna S, Joly B, Philippe L, Kohn M, Malak S, Fouquet G, Daguindau E, Taoufik Y, Lacombe K, Cartron G, Thiéblemont C, Besson C. Duléry R, et al. Am J Hematol. 2021 Aug 1;96(8):934-944. doi: 10.1002/ajh.26209. Epub 2021 May 12. Am J Hematol. 2021. PMID: 33909916 Free PMC article.
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Sehn LH, et al. Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23. Lancet Oncol. 2016. PMID: 27345636 Clinical Trial.
- Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas. Rummel M, et al. Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26655425 Clinical Trial.
- Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F. Palanca-Wessels MC, et al. Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27. Lancet Oncol. 2015. PMID: 25925619 Clinical Trial.
- Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.Plosker GL, Figgitt DP. Plosker GL, et al. Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005. Drugs. 2003. PMID: 12662126 Review.
- The presence of SARS-CoV-2 in multiple clinical specimens of a fatal case of COVID-19: a case report.Sokolovska L, Terentjeva-Decuka A, Cistjakovs M, Nora-Krukle Z, Gravelsina S, Vilmane A, Vecvagare K, Murovska M. Sokolovska L, et al. J Med Case Rep. 2022 Dec 22;16(1):484. doi: 10.1186/s13256-022-03706-y. J Med Case Rep. 2022. PMID: 36550575 Free PMC article.
- Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases.Galusic D, Basic-Kinda S, Pijuk A, Milunovic V, Dreta B, Franjic N, Coha B, Sincic-Petricevic J, Gacina P, Pejsa V, Lucijanic M, Aurer I. Galusic D, et al. Hemasphere. 2022 Nov 15;6(12):e807. doi: 10.1097/HS9.0000000000000807. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36407092 Free PMC article.
- Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era.Zerbit J, Detroit M, Meyer A, Decroocq J, Deau-Fischer B, Deschamps P, Birsen R, Mondesir J, Franchi P, Miekoutima E, Guerin C, Batista R, Bouscary D, Willems L, Vignon M. Zerbit J, et al. Viruses. 2022 Oct 27;14(11):2377. doi: 10.3390/v14112377. Viruses. 2022. PMID: 36366475 Free PMC article.
- Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic health record cohort study.Yue X, Hallett D, Liu Y, Basa E, McNeill A, Dean JP. Yue X, et al. Eur J Haematol. 2023 Feb;110(2):177-187. doi: 10.1111/ejh.13891. Epub 2022 Nov 15. Eur J Haematol. 2023. PMID: 36319588 Free PMC article.
- COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study.Niemann CU, Awan FT, Fogliatto L, Nikitin E, Samoilova O, Habib A, Foroutanpour K, Kuptsova-Clarkson N, Opat S. Niemann CU, et al. Hemasphere. 2022 Sep 22;6(10):e780. doi: 10.1097/HS9.0000000000000780. eCollection 2022 Oct. Hemasphere. 2022. PMID: 36168519 Free PMC article. No abstract available.
-
- Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. - PubMed
-
- OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv[Internet]. [cited 2020 May 19]. Available from: https://www.medrxiv.org/content/10.1101/2020.05.06.20092999v1 - DOI
- Full Text Sources
- Medical
- Miscellaneous
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7599303/bin/gr2.jpg)
References
- Guan W., Ni Z., Hu Y., Liang W., Ou C., He J. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
- Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590.
- Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242.
- Price-Haywood E.G., Burton J., Fort D., Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. N Engl J Med. 2020;0(0) null.
- OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv[Internet]. [cited 2020 May 19]. Available from:
- SPF. Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 - Hémopathies malignes : étude à partir des registres des cancers du réseau Francim [Internet]. [cited 2020 May 21]. Available from:
- Averbuch D., Orasch C., Cordonnier C., Livermore D.M., Mikulska M., Viscoli C. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on infections in leukemia. Haematologica. 2013;98(12):1826–1835.
- Maschmeyer G., De Greef J., Mellinghoff S.C., Nosari A., Thiebaut-Bertrand A., Bergeron A. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) Leukemia. 2019;33(4):844–862.
- Gafter-Gvili A., Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016;57(3):512–519.
- Gea-Banacloche J.C. Rituximab-associated infections. Semin Hematol. 2010;47(2):187–198.
- Tudesq J.-.J., Cartron G., Rivière S., Morquin D., Iordache L., Mahr A. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Autoimmun Rev. 2018;17(2):115–124.
- Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera D.R. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 [cited 2020 Jun 5];0(0). Available from.
- Malard F., Genthon A., Brissot E., van de Wyngaert Z., Marjanovic Z., Ikhlef S. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020:1–5.
- Martín‐Moro F., Marquet J., Piris M., Michael B.M., Sáez A.J., Corona M. Survival study of hospitalized patients with concurrent Covid-19 and haematological malignancies. Br J Haematol. 2020 n/a(n/a). Available from.
- He W., Chen L., Chen L., Yuan G., Fang Y., Chen W. COVID-19 in persons with haematological cancers. Leukemia. 2020 [cited 2020 May 21]; Available from.
- Cottenet J., Dabakuyo-Yonli T.S., Mariet A.-.S., Roussot A., Arveux P., Quantin C. Prevalence of patients hospitalised for male breast cancer in France using the French nationwide hospital administrative database. Eur J Cancer Care Engl. 2019;28(5):e13117.
- Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
- Lei J., Li J., Li X., Qi X. CT Imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;295(1):18.
- Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H. 4th. Vol. 2. IARC; 2008. p. 439 p. (WHO classification of tumours of haematopoietic and lymphoid tissues).
- SPF. COVID-19 : point épidémiologique du 11 juin 2020 [Internet]. [cited 2020 Jun 13]. Available from:
- Vabret N., Britton G.J., Gruber C., Hegde S., Kim J., Kuksin M. Immunology of COVID-19: current state of the science. Immunity. 2020 [cited 2020 May 19]; Available from.
Source: PubMed